Advertisement
Mayo Clinic Proceedings Home

Rare Incidence of Ventricular Tachycardia and Torsades de Pointes in Hospitalized Patients With Prolonged QT Who Later Received Levofloxacin: A Retrospective Study

      Abstract

      Objective

      To determine the incidence of ventricular tachycardia and ventricular fibrillation in patients with prolonged corrected QT interval (QTc) who received levofloxacin through retrospective chart review at a tertiary care teaching hospital in the United States.

      Patients and Methods

      We selected 1004 consecutive hospitalized patients with prolonged QTc (>450 ms) between October 9, 2009 and June 12, 2012 at our institution. Levofloxacin was administered orally and/or intravenously and adjusted to renal function in the inpatient setting. The primary outcome measure was sustained ventricular tachycardia recorded electrocardiographically.

      Results

      With a median time from the start of levofloxacin use to hospital discharge (or death) of 4 days (range, 1-94 days), only 2 patients (0.2%; 95% CI, 0.0%-0.7%) experienced the primary outcome of sustained ventricular tachycardia after the initiation of levofloxacin use.

      Conclusion

      In this study, the short-term risk for sustained ventricular tachycardia in patients with a prolonged QTc who subsequently received levofloxacin was very rare. These results suggest that levofloxacin may be a safe option in patients with prolonged QTc; however, studies with longer follow-up are needed.

      Abbreviations and Acronyms:

      ECG (electrocardiogram), HERG (human-a-go-go-ether-related gene), QTc (corrected QT interval)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lapi F.
        • Wilchesky M.
        • Kezouh A.
        • Benisty J.I.
        • Ernst P.
        • Suissa S.
        Fluoroquinolones and the risk of serious arrhythmia: a population-based study.
        Clin Infect Dis. 2012; 55: 1457-1465
        • Briasoulis A.
        • Agarwal V.
        • Pierce W.J.
        QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
        Cardiology. 2011; 120: 103-110
        • Samaha F.F.
        QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.
        Am J Med. 1999; 107: 528-529
        • Nykamp D.L.
        • Blackmon C.L.
        • Schmidt P.E.
        • Roberson A.G.
        QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.
        Ann Pharmacother. 2005; 39: 543-546
        • Haugaa K.H.
        • Bos J.M.
        • Tarrell R.F.
        • Morlan B.W.
        • Caraballo P.J.
        • Ackerman M.J.
        Institution-wide QT alert system identifies patients with a high risk of mortality.
        Mayo Clin Proc. 2013; 88: 315-325
        • Mosholder A.D.
        • Mathew J.
        • Alexander J.J.
        • Smith H.
        • Nambiar S.
        Cardiovascular risks with azithromycin and other antibacterial drugs.
        N Engl J Med. 2013; 368: 1665-1668
        • Crouch M.A.
        • Limon L.
        • Cassano A.T.
        Clinical relevance and management of drug-related QT interval prolongation.
        Pharmacotherapy. 2003; 23: 881-908
      1. US Food and Drug Administration. Levofloxacin: Highlights of Prescribing Information. 2008. http://www.fda.gov/downloads/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/UCM133684.pdf. Accessed March 16, 2015.

        • Amankwa K.
        • Krishnan S.C.
        • Tisdale J.E.
        Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
        Clin Pharmacol Ther. 2004; 75: 242-247
        • Paltoo B.
        • O’Donoghue S.
        • Mousavi M.S.
        Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.
        Pacing Clin Electrophysiol. 2001; 24: 895-897
        • Bischoff U.
        • Schmidt C.
        • Netzer R.
        • Pongs O.
        Effects of fluoroquinolones on HERG currents.
        Eur J Pharmacol. 2000; 406: 341-343
        • Zünkler B.J.
        • Claassen S.
        • Wos-Maganga M.
        • Rustenbeck I.
        • Holzgrabe U.
        Effects of fluoroquinolones on HERG channels and on pancreatic beta-cell ATP-sensitive K+ channels.
        Toxicology. 2006; 228: 239-248
        • De Bruin M.L.
        • Pettersson M.
        • Meyboom R.H.
        • Hoes A.W.
        • Leufkens H.G.
        Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.
        Eur Heart J. 2005; 26: 590-597
        • Gupta A.
        • Lawrence A.T.
        • Krishnan K.
        • Kavinsky C.J.
        • Trohman R.G.
        Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.
        Am Heart J. 2007; 153: 891-899
        • Noel G.J.
        • Goodman D.B.
        • Chien S.
        • Solanki B.
        • Padmanabhan M.
        • Natarajan J.
        Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
        J Clin Pharmacol. 2004; 44: 464-473
        • Abo-Salem E.
        • Fowler J.C.
        • Attari M.
        • et al.
        Antibiotic-induced cardiac arrhythmias.
        Cardiovasc Ther. 2014; 32: 19-25
        • Patmore L.
        • Fraser S.
        • Mair D.
        • Templeton A.
        Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration.
        Eur J Pharmacol. 2000; 406: 449-452
        • Priori S.G.
        • Wilde A.A.
        • Horie M.
        • et al.
        HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.
        Heart Rhythm. 2013; 10: 1932-1963
        • Patel D.
        • Singh P.
        • Katz W.
        • Hughes C.
        • Chopra K.
        • Nemec J.
        QT interval prolongation in end-stage liver disease cannot be explained by nonhepatic factors.
        Ann Noninvasive Electrocardiol. 2014; 19: 574-581
        • Lannini P.B.
        • Circiumaru I.
        Gatifloxacin-induced QTc prolongation and ventricular tachycardia.
        Pharmacotherapy. 2001; 21: 361-362
        • Owens Jr., R.C.
        Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.
        Pharmacotherapy. 2001; 21: 301-319
      2. CredibleMeds. Resources for healthcare professionals. https://www.crediblemeds.org/everyone/composite-list-all-qtdrugs/. Accessed June 18, 2014.

        • Curtis L.H.
        • Ostbye T.
        • Sendersky V.
        • et al.
        Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients.
        Am J Med. 2003; 114: 135-141
        • Freeman B.D.
        • Dixon D.J.
        • Coopersmith C.M.
        • Zehnbauer B.A.
        • Buchman T.G.
        Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients.
        Pharmacoepidemiol Drug Saf. 2008; 17: 971-981
        • Allen LaPointe N.M.
        • Curtis L.H.
        • Chan K.A.
        • et al.
        Frequency of high-risk use of QT-prolonging medications.
        Pharmacoepidemiol Drug Saf. 2006; 15: 361-368
        • Caillier B.
        • Pilote S.
        • Castonguay A.
        • et al.
        QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile.
        Fundam Clin Pharmacol. 2012; 26: 599-608
        • Letsas K.
        • Korantzopoulos P.
        • Pappas L.
        • Evangelou D.
        • Efremidis M.
        • Kardaras F.
        QT interval prolongation associated with venlafaxine administration.
        Int J Cardiol. 2006; 109: 116-117
        • Alvarez P.A.
        • Pahissa J.
        QT alterations in psychopharmacology: proven candidates and suspects.
        Curr Drug Saf. 2010; 5: 97-104